Max A. Saint-Germain, Patrick Kramer, Carly Weber-Levine, Kelly Jiang, Abdel-Hameed Al-Mistarehi, Kristin J. Redmond, Sang H. Lee, Chetan Bettegowda, Nicholas Theodore, Daniel Lubelski
{"title":"硬脊膜内脊索瘤患者的表现、管理和临床结果:系统性综述","authors":"Max A. Saint-Germain, Patrick Kramer, Carly Weber-Levine, Kelly Jiang, Abdel-Hameed Al-Mistarehi, Kristin J. Redmond, Sang H. Lee, Chetan Bettegowda, Nicholas Theodore, Daniel Lubelski","doi":"10.3171/2024.2.focus2419","DOIUrl":null,"url":null,"abstract":"OBJECTIVE\n<p>Chordomas are locally aggressive neoplasms of the spine or skull base that arise from embryonic remnants of the notochord. Intradural chordomas represent a rare subset of these neoplasms, and few studies have described intradural chordomas in the spine. This review evaluates the presentation, management, and outcomes of intradural spinal chordomas.</p>METHODS\n<p>A systematic review of PubMed/MEDLINE, EMBASE, Cochrane Library, Scopus, and Web of Science was performed. Studies describing at least 1 case of intradural chordomas anywhere in the spine were included. Extracted details included presenting symptoms, radiological findings, treatment course, follow-up, and disease progression.</p>RESULTS\n<p>Thirty-one studies, with a total of 41 patients, were included in this review. Seventy-six percent (31/41) of patients had primary intradural tumors, whereas 24% (10/41) presented with metastasis. The most common signs and symptoms were pain (n = 27, 66%); motor deficits (n = 20, 49%); sensory deficits (n = 17, 42%); and gait disturbance (n = 10, 24%). The most common treatment for intradural chordoma was resection and postoperative radiotherapy. Sixty-six percent (19/29) of patients reported improvement or complete resolution of symptoms after surgery. The recurrence rate was 37% (10/27), and the complication rate was 25% (6/24). The median progression-free survival was 24 months (range 4–72 months). Four patient deaths were reported. The median follow-up time was 12 months (range 13 days–84 months).</p>CONCLUSIONS\n<p>Treatment of intradural spinal chordomas primarily involves resection and radiotherapy. A significant challenge and complication in management is spinal tumor seeding after resection, with 9 studies proposing seeding as a mechanism of tumor metastasis in 11 cases. Factors such as tumor size, Ki-67 positivity, and distant metastasis may correlate with worse outcomes and demonstrate potential as prognostic indicators for intradural spinal chordomas. Further research is needed to improve understanding of this tumor and develop optimal treatment paradigms for these patients.</p>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Characterizing the presentation, management, and clinical outcomes of patients with intradural spinal chordomas: a systematic review\",\"authors\":\"Max A. Saint-Germain, Patrick Kramer, Carly Weber-Levine, Kelly Jiang, Abdel-Hameed Al-Mistarehi, Kristin J. Redmond, Sang H. Lee, Chetan Bettegowda, Nicholas Theodore, Daniel Lubelski\",\"doi\":\"10.3171/2024.2.focus2419\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"OBJECTIVE\\n<p>Chordomas are locally aggressive neoplasms of the spine or skull base that arise from embryonic remnants of the notochord. Intradural chordomas represent a rare subset of these neoplasms, and few studies have described intradural chordomas in the spine. This review evaluates the presentation, management, and outcomes of intradural spinal chordomas.</p>METHODS\\n<p>A systematic review of PubMed/MEDLINE, EMBASE, Cochrane Library, Scopus, and Web of Science was performed. Studies describing at least 1 case of intradural chordomas anywhere in the spine were included. Extracted details included presenting symptoms, radiological findings, treatment course, follow-up, and disease progression.</p>RESULTS\\n<p>Thirty-one studies, with a total of 41 patients, were included in this review. Seventy-six percent (31/41) of patients had primary intradural tumors, whereas 24% (10/41) presented with metastasis. The most common signs and symptoms were pain (n = 27, 66%); motor deficits (n = 20, 49%); sensory deficits (n = 17, 42%); and gait disturbance (n = 10, 24%). The most common treatment for intradural chordoma was resection and postoperative radiotherapy. Sixty-six percent (19/29) of patients reported improvement or complete resolution of symptoms after surgery. The recurrence rate was 37% (10/27), and the complication rate was 25% (6/24). The median progression-free survival was 24 months (range 4–72 months). Four patient deaths were reported. The median follow-up time was 12 months (range 13 days–84 months).</p>CONCLUSIONS\\n<p>Treatment of intradural spinal chordomas primarily involves resection and radiotherapy. A significant challenge and complication in management is spinal tumor seeding after resection, with 9 studies proposing seeding as a mechanism of tumor metastasis in 11 cases. Factors such as tumor size, Ki-67 positivity, and distant metastasis may correlate with worse outcomes and demonstrate potential as prognostic indicators for intradural spinal chordomas. Further research is needed to improve understanding of this tumor and develop optimal treatment paradigms for these patients.</p>\",\"PeriodicalId\":3,\"journal\":{\"name\":\"ACS Applied Electronic Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Electronic Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3171/2024.2.focus2419\",\"RegionNum\":3,\"RegionCategory\":\"材料科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENGINEERING, ELECTRICAL & ELECTRONIC\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3171/2024.2.focus2419","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0
摘要
目的脊索瘤是脊柱或颅底的局部侵袭性肿瘤,由胚胎期残余的脊索产生。硬膜内脊索瘤是此类肿瘤中的罕见亚种,很少有研究描述脊柱硬膜内脊索瘤。本综述评估了硬脊膜内脊索瘤的表现、管理和结果。方法对 PubMed/MEDLINE、EMBASE、Cochrane Library、Scopus 和 Web of Science 进行了系统性综述。纳入的研究至少描述了一例脊柱任何部位的硬膜内脊索瘤病例。结果31项研究共纳入41例患者。76%的患者(31/41)患有原发性硬膜内肿瘤,24%的患者(10/41)患有转移瘤。最常见的体征和症状是疼痛(27 例,66%)、运动障碍(20 例,49%)、感觉障碍(17 例,42%)和步态障碍(10 例,24%)。硬膜内脊索瘤最常见的治疗方法是切除和术后放疗。66%(19/29)的患者报告术后症状有所改善或完全消失。复发率为37%(10/27),并发症发生率为25%(6/24)。无进展生存期中位数为 24 个月(4-72 个月)。有四名患者死亡。结论硬脊膜内脊索瘤的治疗主要包括切除和放疗。治疗中的一个重要挑战和并发症是切除术后脊髓肿瘤播种,9 项研究中的 11 个病例认为播种是肿瘤转移的机制之一。肿瘤大小、Ki-67阳性和远处转移等因素可能与较差的预后相关,并有可能成为硬膜内脊索瘤的预后指标。要加深对这种肿瘤的了解并为这些患者制定最佳治疗方案,还需要进一步的研究。
Characterizing the presentation, management, and clinical outcomes of patients with intradural spinal chordomas: a systematic review
OBJECTIVE
Chordomas are locally aggressive neoplasms of the spine or skull base that arise from embryonic remnants of the notochord. Intradural chordomas represent a rare subset of these neoplasms, and few studies have described intradural chordomas in the spine. This review evaluates the presentation, management, and outcomes of intradural spinal chordomas.
METHODS
A systematic review of PubMed/MEDLINE, EMBASE, Cochrane Library, Scopus, and Web of Science was performed. Studies describing at least 1 case of intradural chordomas anywhere in the spine were included. Extracted details included presenting symptoms, radiological findings, treatment course, follow-up, and disease progression.
RESULTS
Thirty-one studies, with a total of 41 patients, were included in this review. Seventy-six percent (31/41) of patients had primary intradural tumors, whereas 24% (10/41) presented with metastasis. The most common signs and symptoms were pain (n = 27, 66%); motor deficits (n = 20, 49%); sensory deficits (n = 17, 42%); and gait disturbance (n = 10, 24%). The most common treatment for intradural chordoma was resection and postoperative radiotherapy. Sixty-six percent (19/29) of patients reported improvement or complete resolution of symptoms after surgery. The recurrence rate was 37% (10/27), and the complication rate was 25% (6/24). The median progression-free survival was 24 months (range 4–72 months). Four patient deaths were reported. The median follow-up time was 12 months (range 13 days–84 months).
CONCLUSIONS
Treatment of intradural spinal chordomas primarily involves resection and radiotherapy. A significant challenge and complication in management is spinal tumor seeding after resection, with 9 studies proposing seeding as a mechanism of tumor metastasis in 11 cases. Factors such as tumor size, Ki-67 positivity, and distant metastasis may correlate with worse outcomes and demonstrate potential as prognostic indicators for intradural spinal chordomas. Further research is needed to improve understanding of this tumor and develop optimal treatment paradigms for these patients.